MX2013010050A - Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. - Google Patents
Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.Info
- Publication number
- MX2013010050A MX2013010050A MX2013010050A MX2013010050A MX2013010050A MX 2013010050 A MX2013010050 A MX 2013010050A MX 2013010050 A MX2013010050 A MX 2013010050A MX 2013010050 A MX2013010050 A MX 2013010050A MX 2013010050 A MX2013010050 A MX 2013010050A
- Authority
- MX
- Mexico
- Prior art keywords
- lupus
- delanzomib
- treatment
- proteasome inhibitor
- subject
- Prior art date
Links
- 206010025135 lupus erythematosus Diseases 0.000 title abstract 2
- 229940079156 Proteasome inhibitor Drugs 0.000 title 1
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 title 1
- 229950001466 delanzomib Drugs 0.000 title 1
- 239000003207 proteasome inhibitor Substances 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención provee un método para tratamiento de lupus en un sujeto, que comprende la etapa de administrar al sujeto el compuesto A.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161448743P | 2011-03-03 | 2011-03-03 | |
| PCT/US2012/027440 WO2012119056A1 (en) | 2011-03-03 | 2012-03-02 | Proteasome inhibitor delanzomib for use in the treatment of lupus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010050A true MX2013010050A (es) | 2013-11-01 |
| MX343968B MX343968B (es) | 2016-11-30 |
Family
ID=45930987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010050A MX343968B (es) | 2011-03-03 | 2012-03-02 | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9340559B2 (es) |
| EP (1) | EP2680858A1 (es) |
| JP (2) | JP2014506934A (es) |
| CA (1) | CA2827653A1 (es) |
| MX (1) | MX343968B (es) |
| TW (1) | TW201309303A (es) |
| WO (1) | WO2012119056A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201309303A (zh) | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
| US20160250238A1 (en) | 2013-10-03 | 2016-09-01 | Millennium Pharmaceuticals, Inc. | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis |
| US10144761B2 (en) | 2015-06-19 | 2018-12-04 | Hanlin Scientific Inc. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
| CN108473532A (zh) * | 2015-11-02 | 2018-08-31 | 罗切斯特大学 | 硼替佐米缀合物和其使用方法 |
| WO2019040680A1 (en) * | 2017-08-23 | 2019-02-28 | Krzar Life Sciences | IMMUNOPROTEASOME INHIBITORS AND IMMUNOSUPPRESSANT AGENT IN THE TREATMENT OF AUTOIMMUNE DISORDERS |
| CN108624558A (zh) * | 2018-05-16 | 2018-10-09 | 浙江省中医药研究院 | 一种NZW/LacJ狼疮鼠脾淋巴细胞激素耐药模型及其建立方法 |
| CN110540547A (zh) * | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| LT4008721T (lt) | 2004-03-30 | 2024-03-25 | Millennium Pharmaceuticals, Inc. | Borono esterio ir rūgšties junginių sintezė |
| DE102008019916A1 (de) * | 2008-04-11 | 2009-10-29 | Reinhard Dr. Voll | Verfahren zur Eliminierung von langlebigen Plasmazellen |
| EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
| JP5665862B2 (ja) * | 2009-05-27 | 2015-02-04 | セファロン、インク． | Ｃｅｐ−１８７７０とボルテゾミブまたはメルファランを併用する多発性骨髄腫を治療するための併用療法 |
| TW201309303A (zh) | 2011-03-03 | 2013-03-01 | Cephalon Inc | 用於治療狼瘡的蛋白酶體抑制劑 |
-
2012
- 2012-03-01 TW TW101106695A patent/TW201309303A/zh unknown
- 2012-03-02 US US14/002,249 patent/US9340559B2/en not_active Expired - Fee Related
- 2012-03-02 EP EP12712440.2A patent/EP2680858A1/en not_active Withdrawn
- 2012-03-02 WO PCT/US2012/027440 patent/WO2012119056A1/en not_active Ceased
- 2012-03-02 CA CA2827653A patent/CA2827653A1/en not_active Abandoned
- 2012-03-02 MX MX2013010050A patent/MX343968B/es active IP Right Grant
- 2012-03-02 JP JP2013556888A patent/JP2014506934A/ja active Pending
-
2016
- 2016-09-13 JP JP2016178108A patent/JP2017061449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW201309303A (zh) | 2013-03-01 |
| WO2012119056A1 (en) | 2012-09-07 |
| US20130345174A1 (en) | 2013-12-26 |
| JP2017061449A (ja) | 2017-03-30 |
| JP2014506934A (ja) | 2014-03-20 |
| US9340559B2 (en) | 2016-05-17 |
| MX343968B (es) | 2016-11-30 |
| CA2827653A1 (en) | 2012-09-07 |
| EP2680858A1 (en) | 2014-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY165620A (en) | Cyclopropylamines as lsd1 inhibitors | |
| IN2014CN02887A (es) | ||
| MX2019011905A (es) | Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica. | |
| WO2012106735A3 (en) | Plasma-assisted skin treatment | |
| PH12012501719A1 (en) | Compounds for immunoproteasome inhibition | |
| UA110813C2 (uk) | Лікування ліподистрофії | |
| EA033455B1 (ru) | Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе | |
| IN2014CN04634A (es) | ||
| MX343968B (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
| GEP201706690B (en) | Novel process for making compounds for use in treatment of cancer | |
| UA114417C2 (uk) | Інгібітори iap | |
| IN2014DN03464A (es) | ||
| WO2011083482A3 (en) | Method for treatment of psoriasis | |
| IN2014DN00254A (es) | ||
| GB201107985D0 (en) | Process | |
| PH12014502065A1 (en) | Vesicular formulations | |
| PH12014502461A1 (en) | Biomarkers for iap inhibitor therapy | |
| HUE038149T2 (hu) | Eljárás acél kezelésére | |
| AU2012240388A8 (en) | Treatment regimens | |
| MX2014006255A (es) | Tratamientos neurologiocos con metaloporfirina. | |
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
| GB2496723B (en) | Sludge treatment process | |
| IN2014KN01772A (es) | ||
| NZ715554A (en) | Method of treating hypertrophic cardiomyopathy | |
| MX2013006066A (es) | Inhibidor de quinasa janus 2 (jak2) para el tratamiento de lupus. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |